Diabetic CKD (early) — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — SGLT2 inhibitor
Explanation lettering: B = shown as A · E = shown as B · A = shown as D · D = shown as E
KDIGO endorses SGLT2 inhibitors in T2D with CKD and albuminuria for cardio-renal protection, independent of A1c. A/B/D/E: Do not confer the same proven renal outcome benefit.
Reference: https://guidelines.ukkidney.org